Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal Antibodies

Author(s): Rafael Bonamichi-Santos, Mariana Castells

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 45 , 2016

Become EABM
Become Reviewer
Call for Editor


Chemotherapies drugs and monoclonal antibodies are key components of the treatment of cancer patients and patients with chronic inflammatory conditions to provide increase in life expectancy and quality of life. Their increased use has lead to an increase in drugs hypersensitivity reactions (DHR) worldwide. DHR to those agents prevented their use and promoted the use of second line therapies to protect patients’ hypersensitive reactions and anaphylaxis. Second line medications may not fully address the patients’ medical condition and it is desirable to keep patients on first line therapy.

Drug hypersensitivity symptoms can range from mild cutaneous reactions to life-threatening anaphylaxis.

Rapid drug desensitization (RDD) is a novel approach to the management of drug hypersensitivity reactions which are IgE and non-IgE mediated. Through the diferent desensitization protocols patients can receive the full dose of the medications that they have presented a hypersensitive reaction and been protected against anaphylaxis.

This review looks at the current literature on hypersensitivity reactions (HSR) to chemotherapy drugs and monoclonal antibodies and the potential use of RDD for their management.

Keywords: Chemotherapy, Monoclonal antibodies, Rapid drug desensitization, Drug hypersensitivity reaction, Adverse drug reaction.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 25 October, 2016
Page: [6870 - 6880]
Pages: 11
DOI: 10.2174/1381612822666161025154506
Price: $65

Article Metrics

PDF: 95
HTML: 15
PRC: 3